We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 121% below its sector, cheaper than its peers on earnings.
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 095700.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
